Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
BioDrugs
Erschienen in: BioDrugs 1/2004

01.01.2004 | Drug Development

A Multi-Model Approach to Nucleic Acid-Based Drug Development

verfasst von: Dr Isabelle Gautherot, Regís Sodoyer

Erschienen in: BioDrugs | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

With the advent of functional genomics and the shift of interest towards sequence-based therapeutics, the past decades have witnessed intense research efforts on nucleic acid-mediated gene regulation technologies. Today, RNA interference is emerging as a groundbreaking discovery, holding promise for development of genetic modulators of unprecedented potency.
Twenty-five years after the discovery of antisense RNA and ribozymes, gene control therapeutics are still facing developmental difficulties, with only one US FDA-approved antisense drug currently available in the clinic. Limited predictability of target site selection models is recognized as one major stumbling block that is shared by all of the so-called complementary technologies, slowing the progress towards a commercial product.
Currently employed in vitro systems for target site selection include RNAse H-based mapping, antisense oligonucleotide microarrays, and functional screening approaches using libraries of catalysts with randomized target-binding arms to identify optimal ribozyme/DNAzyme cleavage sites. Individually, each strategy has its drawbacks from a drug development perspective. Utilization of message-modulating sequences as therapeutic agents requires that their action on a given target transcript meets criteria of potency and selectivity in the natural physiological environment. In addition to sequence-dependent characteristics, other factors will influence annealing reactions and duplex stability, as well as nucleic acid-mediated catalysis. Parallel consideration of physiological selection systems thus appears essential for screening for nucleic acid compounds proposed for therapeutic applications. Cellular message-targeting studies face issues relating to efficient nucleic acid delivery and appropriate analysis of response. For reliability and simplicity, prokaryotic systems can provide a rapid and cost-effective means of studying message targeting under pseudo-cellular conditions, but such approaches also have limitations.
To streamline nucleic acid drug discovery, we propose a multi-model strategy integrating high-throughputadapted bacterial screening, followed by reporter-based and/or natural cellular models and potentially also in vitro assays for characterization of the most promising candidate sequences, before final in vivo testing.
Literatur
1.
2.
Green PJ, Pines O, Inouye M. The role of antisense RNA in gene regulation. Annu Rev Biochem 1986; 55: 569–97PubMedCrossRef
3.
Wagner EG, Simons RW. Antisense RNA control in bacteria, phages, and plasmids. Annu Rev Microbiol 1994; 48: 713–42PubMedCrossRef
4.
Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988; 334(6183): 585–91PubMedCrossRef
5.
6.
Buzayan JM, Hampel A, Bruening G. Nucleotide sequence and newly formed phosphodiester bond of spontaneously ligated satellite tobacco ringspot virus RNA. Nucleic Acids Res 1986; 14(24): 9729–43PubMedCrossRef
7.
Davies C, Haseloff J, Symons RH. Structure, self-cleavage, and replication of two viroid-like satellite RNAs (virusoids) of subterranean clover mottle virus. Virology 1990; 177(1): 216–24PubMedCrossRef
8.
Hutchins CJ, Rathjen PD, Forster AC, et al. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res 1986; 14(9): 3627–40PubMedCrossRef
9.
Kruger K, Grabowski PJ, Zaug AJ, et al. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982; 31(1): 147–57PubMedCrossRef
10.
Prody GA, Bakos JT, Buzayan JM, et al. Autolytic processing of dimeric plant virus satellite RNA. Science 1986; 231: 1577–81PubMedCrossRef
11.
Sharmeen L, Kuo MY, Dinter-Gottlieb G, et al. Antigenomic RNA of human hepatitis delta virus can undergo self-cleavage. J Virol 1988; 62(8): 2674–9PubMed
12.
Symons RH, Hutchins CJ, Forster AC, et al. Self-cleavage of RNA in the replication of viroids and virusoids. J Cell Sci Suppl 1987; 7: 303–18PubMed
13.
Guerrier-Takada C, Gardiner K, Marsh T, et al. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 1983; 35 (3 Pt 2): 849–57PubMedCrossRef
14.
Nissen P, Hansen J, Ban N, et al. The structural basis of ribosome activity in peptide bond synthesis. Science 2000; 289(5481): 920–30PubMedCrossRef
15.
Saville BJ, Collins RA. A site-specific self-cleavage reaction performed by a novel RNA in neurospora mitochondria. Cell 1990; 61(4): 685–96PubMedCrossRef
16.
17.
Valadkhan S, Manley JL. Splicing-related catalysis by protein-free snRNAs. Nature 2001; 413(6857): 701–7PubMedCrossRef
18.
19.
Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A 1997; 94(9): 4262–6PubMedCrossRef
20.
Breaker RR. Engineered allosteric ribozymes as biosensor components. Curr Opin Biotechnol 2002; 13(1): 31–9PubMedCrossRef
21.
Iyo M, Kawasaki H, Taira K. Allosterically controllable maxizymes for molecular gene therapy. Curr Opin Mol Ther 2002; 4(2): 154–65PubMed
22.
Silverman SK. Rube Goldberg goes (ribo)nuclear? Molecular switches and sensors made from RNA. RNA 2003; 9(4): 377–83PubMedCrossRef
23.
Soukup GA, Breaker RR. Nucleic acid molecular switches. Trends Biotechnol 1999; 17(12): 469–76PubMedCrossRef
24.
Koller E, Gaarde WA, Monia BP. Elucidating cell signaling mechanisms using antisense technology. Trends Pharmacol Sci 2000; 21(4): 142–8PubMedCrossRef
25.
Cech TR. Ribozyme engineering. Curr Opin Struct Biol 1992; 2: 605–9CrossRef
26.
Christoffersen RE, Marr JJ. Ribozymes as human therapeutic agents. J Med Chem 1995; 38(12): 2023–37PubMedCrossRef
27.
Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 2002; 1(7): 503–14PubMedCrossRef
28.
Steele D, Kertsburg A, Soukup G. Engineered catalytic RNA and DNA: new biochemical tools for drug discovery and design. Am J Pharmacogenomics 2003; 3(2): 131–44PubMedCrossRef
29.
Sun LQ, Cairns MJ, Saravolac EG, et al. Catalytic nucleic acids: from lab to applications. Pharmacol Rev 2000; 52(3): 325–47PubMed
30.
AIDS. ORG, Inc. Fomivirsen approved for CMV retinitis: first antisense drug. AIDS Treatment News 1998 Sep 4; Issue 302: 7
31.
de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen: a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm 1999; 7(3-4): 189–98PubMedCrossRef
32.
Roehr B. Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care 1998; 4(10): 14–6PubMed
33.
Amado RG, Mitsuyasu RT, Symonds G, et al. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther 1999; 10(13): 2255–70PubMedCrossRef
34.
Feng Y, Leavitt M, Tritz R, et al. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology 2000; 276(2): 271–8PubMedCrossRef
35.
Khuri FR, Kurie JM. Antisense approaches enter the clinic. Clin Cancer Res 2000; 6(5): 1607–10PubMed
36.
Usman N, Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 2000; 106(10): 1197–202PubMedCrossRef
37.
Wong-Staal F, Poeschla EM, Looney DJ. A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther 1998; 9(16): 2407–25PubMedCrossRef
38.
Morris MJ, Tong WP, Cordon-Cardo C, et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002 Mar; 8(3): 679–83PubMed
39.
40.
Cripps MC, Figueredo AT, Oza AM, et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res 2002 Jul; 8(7): 2188–92PubMed
41.
42.
Coudert B, Anthoney A, Fiedler W, et al. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer: a European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur J Cancer 2001 Nov; 37(17): 2194–8PubMedCrossRef
43.
Adjei AA, Dy GK, Erlichman C, et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 2003 Jan; 9(1): 115–23PubMed
44.
45.
46.
Yu RZ, Su JQ, Grundy JS, et al. Prediction of clinical responses in a simulated phase III trial of Crohn’s patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens. Antisense Nucleic Acid Drug Dev 2003 Feb; 13(1): 57–66PubMedCrossRef
47.
48.
49.
Fjose A, Ellingsen S, Wargelius A, et al. RNA interference: mechanisms and applications. Biotechnol Annu Rev 2001; 7: 31–57PubMedCrossRef
50.
Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001; 2(2): 110–9PubMedCrossRef
51.
52.
Bertrand JR, Pottier M, Vekris A, et al. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002; 296(4): 1000–4PubMedCrossRef
53.
Caplen NJ, Parrish S, Imani F, et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci U S A 2001; 98(17): 9742–7PubMedCrossRef
54.
Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411(6836): 494–8PubMedCrossRef
55.
Elbashir SM, Martinez J, Patkaniowska A, et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001; 20(23): 6877–88PubMedCrossRef
56.
Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391(6669): 806–11PubMedCrossRef
57.
Miyagishi M, Hayashi M, Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 2003; 13(1): 1–7PubMedCrossRef
58.
Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science 1993; 261(5124): 1004–12PubMedCrossRef
59.
Dean NM, McKay R, Condon TP, et al. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 1994; 269(23): 16416–24PubMed
60.
Monia BP, Johnston JF, Geiger T, et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996; 2(6): 668–75PubMedCrossRef
61.
Peyman A, Helsberg M, Kretzschmar G, et al. Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. Biol Chem Hoppe Seyler 1995; 376(3): 195–8PubMedCrossRef
62.
Harborth J, Elbashir SM, Bechert K, et al. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 2001; 114 (Pt 24): 4557–65PubMed
63.
Holen T, Amarzguioui M, Wiiger MT, et al. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res 2002; 30(8): 1757–66PubMedCrossRef
64.
Yang D, Buchholz F, Huang Z, et al. Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2002; 99(15): 9942–7PubMedCrossRef
65.
Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci U S A 1977; 74(10): 4370–4PubMedCrossRef
66.
Liebhaber SA, Cash F, Eshleman SS. Translation inhibition by an mRNA coding region secondary structure is determined by its proximity to the AUG initiation codon. J Mol Biol 1992; 226(3): 609–21PubMedCrossRef
67.
Vickers TA, Wyatt JR, Burckin T, et al. Fully modified 2′MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res 2001; 29(6): 1293–9PubMedCrossRef
68.
Sazani P, Kole R. Modulation of alternative splicing by antisense oligonucleotides. Prog Mol Subcell Biol 2003; 31: 217–39PubMed
69.
Dash P, Lotan I, Knapp M, et al. Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc Natl Acad Sci U S A 1987; 84(22): 7896–900PubMedCrossRef
70.
Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A 1988; 85(14): 5011–5PubMedCrossRef
71.
Dahm SC, Uhlenbeck OC. Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry 1991; 30(39): 9464–9PubMedCrossRef
72.
Faulhammer D, Famulok M. Characterization and divalent metal-ion dependence of in vitro selected deoxyribozymes which cleave DNA/RNA chimeric oligonucleotides. J Mol Biol 1997; 269(2): 188–202PubMedCrossRef
73.
Li J, Zheng W, Kwon AH, et al. In vitro selection and characterization of a highly efficient Zn (II)-dependent RNA-cleaving deoxyribozyme. Nucleic Acids Res 2000; 28(2): 481–8PubMedCrossRef
74.
Eckstein F. The hammerhead ribozyme. Biochem Soc Trans 1996; 24(3): 601–4PubMed
75.
Perriman R, Delves A, Gerlach WL. Extended target-site specificity for a hammerhead ribozyme. Gene 1992; 113(2): 157–63PubMedCrossRef
76.
Ruffner DE, Stormo GD, Uhlenbeck OC. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 1990; 29(47): 10695–702PubMedCrossRef
77.
Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci U S A 2002; 99(3): 1443–8PubMedCrossRef
78.
Scherr M, Morgan MA, Eder M. Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem 2003; 10(3): 245–56PubMedCrossRef
79.
Dorai T, Goluboff ET, Olsson CA, et al. Development of a hammerhead ribozyme against BCL-2: II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res 1997; 17(5A): 3307–12PubMed
80.
Ohta Y, Kijima H, Kashani-Sabet M, et al. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J Invest Dermatol 1996; 106(2): 275–80PubMedCrossRef
81.
Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci U S A 1993; 90(18): 8673–7PubMedCrossRef
82.
Friedman KJ, Kole J, Cohn JA, et al. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem 1999; 274(51): 36193–9PubMedCrossRef
83.
van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001; 10(15): 1547–54PubMedCrossRef
84.
Bohula EA, Salisbury AJ, Sohail M, et al. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem 2003; 278(18): 15991–7PubMedCrossRef
85.
Portman DS, Dreyfuss G. RNA annealing activities in HeLa nuclei. EMBO J 1994; 13(1): 213–21PubMed
86.
Vickers T, Baker BF, Cook PD, et al. Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res 1991; 19(12): 3359–68PubMedCrossRef
87.
Xing Z, Whitton JL. Ribozymes which cleave arenavirus RNAs: identification of susceptible target sites and inhibition by target site secondary structure. J Virol 1992; 66(3): 1361–9PubMed
88.
Campbell TB, Cech TR. Identification of ribozymes within a ribozyme library that efficiently cleave a long substrate RNA. RNA 1995; 1(6): 598–609PubMed
89.
Goodchild J. Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2′-O-methylation. Nucleic Acids Res 1992; 20(17): 4607–12PubMedCrossRef
90.
Heidenreich O, Eckstein F. Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. J Biol Chem 1992; 267(3): 1904–9PubMed
91.
Toschi N. Influence of mRNA self-structure on hybridization: computational tools for antisense sequence selection. Methods 2000; 22(3): 261–9PubMedCrossRef
92.
Zuker M. On finding all suboptimal foldings of an RNA molecule. Science 1989; 244(4900): 48–52PubMedCrossRef
93.
Hendry P, McCall MJ, Lockett TJ. Design of hybridizing arms in hammerhead ribozymes. Methods Mol Biol 1997; 74: 253–64PubMed
94.
Jarvis TC, Wincott FE, Alby LJ, et al. Optimizing the cell efficacy of synthetic ribozymes: site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J Biol Chem 1996; 271(46): 29107–12PubMedCrossRef
95.
Patzel V, Sczakiel G. Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells. Nat Biotechnol 1998; 16(1): 64–8PubMedCrossRef
96.
Isambert H, Siggia ED. Modeling RNA folding paths with pseudoknots: application to hepatitis delta virus ribozyme. Proc Natl Acad Sci U S A 2000; 97(12): 6515–20PubMedCrossRef
97.
Pan T, Artsimovitch I, Fang XW, et al. Folding of a large ribozyme during transcription and the effect of the elongation factor NusA. Proc Natl Acad Sci U S A 1999; 96(17): 9545–50PubMedCrossRef
98.
Rivas E, Eddy SR. A dynamic programming algorithm for RNA structure prediction including pseudoknots. J Mol Biol 1999; 285(5): 2053–68PubMedCrossRef
99.
100.
Birikh KR, Berlin YA, Soreq H, et al. Probing accessible sites for ribozymes on human acetylcholinesterase RNA. RNA 1997; 3(4): 429–37PubMed
101.
Dropulic B, Jeang KT. Intracellular susceptibility to ribozymes in a tethered substrate-ribozyme provirus model is not predicted by secondary structures of human immunodeficiency virus type 1 RNAs in vitro. Antisense Res Dev 1994; 4(3): 217–21PubMed
102.
Hendrix C, Anne J, Joris B, et al. Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA. Biochem J 1996; 314 (Pt 2): 655–61PubMed
103.
Patzel V, Steidl U, Kronenwett R, et al. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res 1999; 27(22): 4328–34PubMedCrossRef
104.
Gultyaev AP, van Batenburg FH, Pleij CW. The computer simulation of RNA folding pathways using a genetic algorithm. J Mol Biol 1995; 250(1): 37–51PubMedCrossRef
105.
Juan V, Wilson C. RNA secondary structure prediction based on free energy and phylogenetic analysis. J Mol Biol 1999; 289(4): 935–47PubMedCrossRef
106.
Ho SP, Britton DH, Stone BA, et al. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNAaccessible sites with oligonucleotide libraries. Nucleic Acids Res 1996; 24(10): 1901–7PubMedCrossRef
107.
Ho SP, Bao Y, Lesher T, et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol 1998; 16(1): 59–63PubMedCrossRef
108.
Lima WF, Brown-Driver V, Fox M, et al. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J Biol Chem 1997; 272(1): 626–38PubMedCrossRef
109.
Inoue H, Hayase Y, Iwai S, et al. Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett 1987; 215(2): 327–30PubMedCrossRef
110.
Lima WF, Mohan V, Crooke ST. The influence of antisense oligonucleotideinduced RNA structure on Escherichia coli RNase H1 activity. J Biol Chem 1997; 272(29): 18191–9PubMedCrossRef
111.
Campbell TB, McDonald CK, Hagen M. The effect of structure in a long target RNA on ribozyme cleavage efficiency. Nucleic Acids Res 1997; 25(24): 4985–93PubMedCrossRef
112.
Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol 1997; 15(6): 537–41PubMedCrossRef
113.
Sohail M, Southern EM. Selecting optimal antisense reagents. Adv Drug Deliv Rev 2000; 44(1): 23–34PubMedCrossRef
114.
Sohail M, Southern EM. Oligonucleotide scanning arrays: application to highthroughput screening for effective antisense reagents and the study of nucleic acid interactions. Adv Biochem Eng Biotechnol 2002; 77: 43–56PubMed
115.
Semizarov D, Frost L, Sarthy A, et al. Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A 2003; 100(11): 6347–52PubMedCrossRef
116.
Bergeron LJ, Perreault JP. Development and comparison of procedures for the selection of delta ribozyme cleavage sites within the hepatitis B virus. Nucleic Acids Res 2002; 30(21): 4682–91PubMedCrossRef
117.
Lieber A, Strauss M. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol Cell Biol 1995; 15(1): 540–51PubMed
118.
Pierce ML, Ruffner DE. Construction of a directed hammerhead ribozyme library: towards the identification of optimal target sites for antisense-mediated gene inhibition. Nucleic Acids Res 1998; 26(22): 5093–101PubMedCrossRef
119.
Sriram B, Banerjea AC. In vitro-selected RNA cleaving DNA enzymes from a combinatorial library are potent inhibitors of HIV-1 gene expression. Biochem J 2000; 352 Pt 3: 667–73PubMedCrossRef
120.
Yu Q, Pecchia DB, Kingsley SL, et al. Cleavage of highly structured viral RNA molecules by combinatorial libraries of hairpin ribozymes: the most effective ribozymes are not predicted by substrate selection rules. J Biol Chem 1998; 273(36): 23524–33PubMedCrossRef
121.
Bertrand EL, Rossi JJ. Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J 1994; 13(12): 2904–12PubMed
122.
Tsuchihashi Z, Khosla M, Herschlag D. Protein enhancement of hammerhead ribozyme catalysis. Science 1993; 262(5130): 99–102PubMedCrossRef
123.
Bassi GS, Mollegaard NE, Murchie AI, et al. Ionic interactions and the global conformations of the hammerhead ribozyme. Nat Struct Biol 1995; 2(1): 45–55PubMedCrossRef
124.
De Rose VJ. Metal ion binding to catalytic RNA molecules. Curr Opin Struct Biol 2003; 13(3): 317–24CrossRef
125.
Menger M, Tuschl T, Eckstein F, et al. Mg (2+)-dependent conformational changes in the hammerhead ribozyme. Biochemistry 1996; 35(47): 14710–6PubMedCrossRef
126.
Uchida T, Takamoto K, He Q, et al. Multiple monovalent ion-dependent pathways for the folding of the L-21 Tetrahymena thermophila ribozyme. J Mol Biol 2003; 328(2): 463–78PubMedCrossRef
127.
128.
129.
Oberosler P, Hloch P, Ramsperger U, et al. p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J 1993; 12(6): 2389–96PubMed
130.
Wu L, Bayle JH, Elenbaas B, et al. Alternatively spliced forms in the carboxyterminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol Cell Biol 1995; 15(1): 497–504PubMed
131.
Kumar A, Wilson SH. Studies of the strand-annealing activity of mammalian hnRNP complex protein Al. Biochemistry 1990; 29(48): 10717–22PubMedCrossRef
132.
Pontius BW, Berg P. Renaturation of complementary DNA strands mediated by purified mammalian heterogeneous nuclear ribonucleoprotein Al protein: implications for a mechanism for rapid molecular assembly. Proc Natl Acad Sci U S A 1990; 87(21): 8403–7PubMedCrossRef
133.
Antony T, Thomas T, Shirahata A, et al. Selectivity of spermine homologs on triplex DNA stabilization. Antisense Nucleic Acid Drug Dev 1999; 9(2): 221–31PubMedCrossRef
134.
Hammann C, Hormes R, Sczakiel G, et al. A spermidine-induced conformational change of long-armed hammerhead ribozymes: ionic requirements for fast cleavage kinetics. Nucleic Acids Res 1997; 25(23): 4715–22PubMedCrossRef
135.
Musso M, Thomas T, Shirahata A, et al. Effects of chain length modification and bis (ethyl) substitution of spermine analogs on purine-purine-pyrimidine triplex DNA stabilization, aggregation, and conformational transitions. Biochemistry 1997; 36(6): 1441–9PubMedCrossRef
136.
Saminathan M, Thomas T, Shirahata A, et al. Polyamine structural effects on the induction and stabilization of liquid crystalline DNA: potential applications to DNA packaging, gene therapy and polyamine therapeutics. Nucleic Acids Res 2002; 30(17): 3722–31PubMedCrossRef
137.
Woolf TM, Melton DA, Jennings CG. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci U S A 1992; 89(16): 7305–9PubMedCrossRef
138.
De Young MB, Kincade-Denker J, Boehm CA, et al. Functional characterization of ribozymes expressed using U1 and T7 vectors for the intracellular cleavage of ANF mRNA. Biochemistry 1994; 33(40): 12127–38PubMedCrossRef
139.
Scherr M, Rossi JJ. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Res 1998; 26(22): 5079–85PubMedCrossRef
140.
Scherr M, Rossi JJ, Sczakiel G, et al. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res 2000; 28(13): 2455–61PubMedCrossRef
141.
Akhtar S, Kole R, Juliano RL. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci 1991; 49(24): 1793–801PubMedCrossRef
142.
Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 1986; 13(2): 97–102PubMedCrossRef
143.
Agrawal S, Iyer RP. Modified oligonucleotides as therapeutic and diagnostic agents. Curr Opin Biotechnol 1995; 6(1): 12–9PubMedCrossRef
144.
Agrawal S, Jiang Z, Zhao Q, et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci U S A 1997; 94(6): 2620–5PubMedCrossRef
145.
Beigelman L, McSwiggen JA, Draper KG, et al. Chemical modification of hammerhead ribozymes: catalytic activity and nuclease resistance. J Biol Chem 1995; 270(43): 25702–8PubMedCrossRef
146.
Hughes MD, Hussain M, Nawaz Q, et al. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001; 6(6): 303–15PubMedCrossRef
147.
Schmajuk G, Sierakowska H, Kole R. Antisense oligonucleotides with different backbones: modification of splicing pathways and efficacy of uptake. J Biol Chem 1999; 274(31): 21783–9PubMedCrossRef
148.
Audouy S, Hoekstra D. Cationic lipid-mediated transfection in vitro and in vivo (review). Mol Membr Biol 2001; 18(2): 129–43PubMedCrossRef
149.
Dass CR. Liposome-mediated delivery of oligodeoxynucleotides in vivo. Drug Deliv 2002; 9(3): 169–80PubMedCrossRef
150.
Maurer N, Mori A, Palmer L, et al. Lipid-based systems for the intracellular delivery of genetic drugs. Mol Membr Biol 1999; 16(1): 129–40PubMedCrossRef
151.
Benimetskaya L, Takle GB, Vilenchik M, et al. Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides. Nucleic Acids Res 1998; 26(23): 5310–7PubMedCrossRef
152.
Boussif O, Lezoualc’h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 1995; 92(16): 7297–301PubMedCrossRef
153.
Flynn SM, George ST, White L, et al. Water-soluble, meso-substituted cationic porphyrins: a family of compounds for cellular delivery of oligonucleotides. Biotechniques 1999; 26(4): 736–42, 744, 746PubMed
154.
Leonetti JP, Degols G, Lebleu B. Biological activity of oligonucleotide-poly (Llysine) conjugates: mechanism of cell uptake. Bioconjug Chem 1990; 1(2): 149–53PubMedCrossRef
155.
Bongartz JP, Aubertin AM, Milhaud PG, et al. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res 1994; 22(22): 4681–8PubMedCrossRef
156.
Morris MC, Vidal P, Chaloin L, et al. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 1997; 25(14): 2730–6PubMedCrossRef
157.
Wagner E, Plank C, Zatloukal K, et al. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci U S A 1992; 89(17): 7934–8PubMedCrossRef
158.
Fisher AA, Ye D, Sergueev DS, et al. Evaluating the specificity of antisense oligonucleotide conjugates: a DNA array analysis. J Biol Chem 2002; 277(25): 22980–4PubMedCrossRef
159.
Ho A, Schwarze SR, Mermelstein SJ, et al. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 2001; 61(2): 474–7PubMed
160.
Czubayko F, Downing SG, Hsieh SS, et al. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Ther 1997; 4(9): 943–9PubMedCrossRef
161.
162.
Horster A, Teichmann B, Hormes R, et al. Recombinant AAV-2 harboring gfpantisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy. Gene Ther 1999; 6(7): 1231–8PubMedCrossRef
163.
Li M, Lonial H, Citarella R, et al. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. Cancer Gene Ther 1996; 3(4): 221–9PubMed
164.
Potter PM, McKenzie PP, Hussain N, et al. Construction of adenovirus for high level expression of small RNAs in mammalian cells: application to a Bcl-2 ribozyme. Mol Biotechnol 2000; 15(2): 105–14PubMedCrossRef
165.
Vacek MM, Ma H, Gemignani F, et al. High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. Blood 2003; 101(1): 104–11PubMedCrossRef
166.
Spiller DG, Giles RV, Grzybowski J, et al. Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation. Blood 1998; 91(12): 4738–46PubMed
167.
Freedland SJ, Malone RW, Borchers HM, et al. Toxicity of cationic lipidribozyme complexes in human prostate tumor cells can mimic ribozyme activity. Biochem Mol Med 1996; 59(2): 144–53PubMedCrossRef
168.
Amarzguioui M, Prydz H. Hammerhead ribozyme design and application. Cell Mol Life Sci 1998; 54(11): 1175–202PubMedCrossRef
169.
Chang MY, Won SJ, Liu HS. A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines. J Cancer Res Clin Oncol 1997; 123(2): 91–9PubMedCrossRef
170.
Chen Y, Ji YJ, Conrad C. Expression of ssDNA in mammalian cells. Biotechniques 2003; 34(1): 167–71PubMed
171.
Denman RB, Smedman M, Ju W, et al. Ribozyme mediated degradation of betaamyloid peptide precursor mRNA in COS-7 cells. Nucleic Acids Res 1994; 22(12): 2375–82PubMedCrossRef
172.
Hubinger G, Schmid M, Linortner S, et al. Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells. Exp Hematol 2001; 29(10): 1226–35PubMedCrossRef
173.
Yang PY, Rui YC, Jin YX, et al. Antisense oligodeoxynucleotide inhibits vascular endothelial growth factor expression in U937 foam cells. Acta Pharmacol Sin 2003; 24(6): 610–4PubMed
174.
Daly C, Coyle S, McBride S, et al. mdrl ribozyme mediated reversal of the multidrug resistant phenotype in human lung cell lines. Cytotechnology 1996; 19(3): 199–205PubMedCrossRef
175.
Feng M, Cabrera G, Deshane J, et al. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995; 55(10): 2024–8PubMed
176.
Kashani-Sabet M, Funato T, Tone T, et al. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev 1992; 2(1): 3–15PubMed
177.
Ohta Y, Kijima H, Ohkawa T, et al. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res 1996; 24(5): 938–42PubMedCrossRef
178.
Su Z, Goldstein NI, Fisher PB. Antisense inhibition of the PTI-1 oncogene reverses cancer phenotypes. Proc Natl Acad Sci U S A 1998; 95(4): 1764–9PubMedCrossRef
179.
Brukner I, Tremblay GA. Cellular proteins prevent antisense phosphorothioate oligonucleotide (SdT18) to target sense RNA (rA18): development of a new in vitro assay. Biochemistry 2000; 39(37): 11463–6PubMedCrossRef
180.
Chavany C, Connell Y, Neckers L. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 1995; 48(4): 738–46PubMed
181.
Lebedeva I, Stein CA. Antisense oligonucleotides: promise and reality. Annu Rev Pharmacol Toxicol 2001; 41: 403–19PubMedCrossRef
182.
Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 1994; 4(2): 67–9PubMed
183.
184.
Butler M, Stecker K, Bennett CF. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 1997; 77(4): 379–88PubMed
185.
Graham MJ, Crooke ST, Monteith DK, et al. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 1998; 286(1): 447–58PubMed
186.
Harborth J, Elbashir SM, Vandenburgh K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 2003; 13(2): 83–105PubMedCrossRef
187.
Wang H, Davis A, Yu S, et al. Response of cancer cells to molecular interruption of the CK2 signal. Mol Cell Biochem 2001; 227(1-2): 167–74PubMedCrossRef
188.
Didier M, Xu M, Berman SA, et al. Involvement of three glutamate receptor epsilon subunits in the formation of N-methyl-D-aspartate receptors mediating excitotoxicity in primary cultures of mouse cerebellar granule cells. Neuroscience 1997; 78(4): 1129–46PubMedCrossRef
189.
Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003; 9(7): 2826–36PubMed
190.
Seyhan AA, Amaral J, Burke JM. Intracellular RNA cleavage by the hairpin ribozyme. Nucleic Acids Res 1998; 26(15): 3494–504PubMedCrossRef
191.
Yamaguchi K, Papp B, Zhang D, et al. The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1997; 13(7): 545–54PubMedCrossRef
192.
Arinobu Y, Atamas SP, Otsuka T, et al. Antagonistic effects of an alternative splice variant of human IL-4, IL-4delta2, on IL-4 activities in human monocytes and B cells. Cell Immunol 1999; 191(2): 161–7PubMedCrossRef
193.
Garcia-Fernandez MO, Schally AV, Varga JL, et al. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat 2003; 77(1): 15–26PubMedCrossRef
194.
Krobert KA, Levy FO. The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects. Br J Pharmacol 2002; 135(6): 1563–71PubMedCrossRef
195.
Smith C. A question of form. Nature 2003; 422(6929): 341
196.
Smith DE, Hanna R, Delia F, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003; 18(1): 87–96PubMedCrossRef
197.
Albuquerque-Silva J, Houard S, Bollen A. Tailing cDNAs with terminal deoxynucleotidyl transferase in RT-PCR assays to identify ribozyme cleavage products. Nucleic Acids Res 1998; 26(13): 3314–6PubMedCrossRef
198.
Chen HH, Castanotto D, LeBon JM, et al. In vivo, high-resolution analysis of yeast and mammalian RNA-protein interactions, RNA structure, RNA splicing and ribozyme cleavage by use of terminal transferase-dependent PCR. Nucleic Acids Res 2000; 28(7): 1656–64PubMedCrossRef
199.
Ohkawa J, Koguma T, Kohda T, et al. Ribozymes: from mechanistic studies to applications in vivo. J Biochem (Tokyo) 1995; 118(2): 251–8
200.
Thoma C, Hasselblatt P, Kock J, et al. Generation of stable mRNA fragments and translation of N-truncated proteins induced by antisense oligodeoxynucleotides. Mol Cell 2001; 8(4): 865–72PubMedCrossRef
201.
Koseki S, Ohkawa J, Yamamoto R, et al. A simple assay system for examination of the inhibitory potential in vivo of decoy RNAs, ribozymes and other drugs by measuring the Tat-mediated transcription of a fusion gene composed of the long terminal repeat of HIV-1 and a gene for luciferase. J Control Release 1998; 53(1-3): 159–73PubMedCrossRef
202.
Lim W, Furlow JD. Ribozyme suppression of endogenous thyroid hormone receptor activity in Xenopus laevis cells. Nucleic Acids Res 2002; 30(15): 3490–6PubMedCrossRef
203.
Scherr M, Maurer AB, Klein S, et al. Effective reversal of a transformed phenotype by retrovirus-mediated transfer of a ribozyme directed against mutant N-ras. Gene Ther 1998; 5(9): 1227–34PubMedCrossRef
204.
Gemignani F, Sazani P, Morcos P, et al. Temperature-dependent splicing of betaglobin pre-mRNA. Nucleic Acids Res 2002; 30(21): 4592–8PubMedCrossRef
205.
Grunweller A, Wyszko E, Bieber B, et al. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 2003; 31(12): 3185–93PubMedCrossRef
206.
Passman M, Weinberg M, Kew M, et al. In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun 2000; 268(3): 728–33PubMedCrossRef
207.
Sazani P, Kang SH, Maier MA, et al. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res 2001; 29(19): 3965–74PubMed
208.
Gautherot I, Burdin N, Seguin D, et al. Cloning of interleukin-4 delta2 splice variant (IL-4delta2) in chimpanzee and cynomolgus macaque: phylogenetic analysis of delta2 splice variant appearance, and implications for the study of IL-4-driven immune processes. Immunogenetics 2002; 54(9): 635–44PubMedCrossRef
209.
Aoki Y, Cioca DP, Oidaira H, et al. RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol 2003; 30(1-2): 96–102PubMedCrossRef
210.
Chiu YL, Rana TM. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell 2002; 10(3): 549–61PubMedCrossRef
211.
McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature 2002; 418(6893): 38–9PubMedCrossRef
212.
McCaffrey AP, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21(6): 639–44PubMedCrossRef
213.
Xia H, Mao Q, Paulson HL, et al. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20(10): 1006–10PubMedCrossRef
214.
Silver S, Clark D. Magnesium transport in Escherichia coli. J Biol Chem 1971; 246(3): 569–76PubMed
215.
Sioud M, Drlica K. Prevention of human immunodeficiency virus type 1 integrase expression in Escherichia coli by a ribozyme. Proc Natl Acad Sci U S A 1991; 88(16): 7303–7PubMedCrossRef
216.
Fujita S, Koguma T, Ohkawa J, et al. Discrimination of a single base change in a ribozyme using the gene for dihydrofolate reductase as a selective marker in Escherichia coli. Proc Natl Acad Sci U S A 1997; 94(2): 391–6PubMedCrossRef
217.
Koguma T, Ohkawa J, Mori K, et al. A novel screening system for construction and selection of active ribozymes using DHFR (dihydrofolate reductase) gene as selection marker. Nucleic Acids Symp Ser 1995; 34: 221–2PubMed
218.
Chuat JC, Galibert F. Can ribozymes be used to regulate procaryote gene expression? Biochem Biophys Res Commun 1989; 162(3): 1025–9PubMedCrossRef
219.
Junn E, Kang C. Detection of hammerhead ribozyme-mediated cleavage and reduced expression of LacZ′mRNA in E. coli. Genet Anal 1996; 13(1): 1–7PubMedCrossRef
220.
Tatout C, Gauthier E, Pinon H. Rapid evaluation in Escherichia coli of antisense RNAs and ribozymes. Lett Appl Microbiol 1998; 27(5): 297–301PubMedCrossRef
221.
222.
Arndt GM, Rank GH. Colocalization of antisense RNAs and ribozymes with their target mRNAs. Genome 1997; 40(6): 785–97PubMedCrossRef
223.
Sullenger BA. Colocalizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors. Appl Biochem Biotechnol 1995; 54(1-3): 57–61PubMedCrossRef
224.
Kanaya S, Ikehara M. Functions and structures of ribonuclease H enzymes. Subcell Biochem 1995; 24: 377–422PubMed
225.
Meunier L, Mayer R, Monsigny M, et al. The nuclear export signal-dependent localization of oligonucleopeptides enhances the inhibition of the protein expression from a gene transcribed in cytosol. Nucleic Acids Res 1999; 27(13): 2730–6PubMedCrossRef
226.
Amarzguioui M, Brede G, Babaie E, et al. Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes. Nucleic Acids Res 2000; 28(21): 4113–24PubMedCrossRef
227.
Jayaraman A, Walton SP, Yarmush ML, et al. Rational selection and quantitative evaluation of antisense oligonucleotides. Biochim Biophys Acta 2001; 1520(2): 105–14PubMedCrossRef
228.
Lehmann MJ, Patzel V, Sczakiel G. Theoretical design of antisense genes with statistically increased efficacy. Nucleic Acids Res 2000; 28(13): 2597–604PubMedCrossRef
229.
Laptev AV, Lu Z, Colige A, et al. Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides: the most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA. Biochemistry 1994; 33(36): 11033–9PubMedCrossRef
230.
Matveeva O, Felden B, Audlin S, et al. A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures. Nucleic Acids Res 1997; 25(24): 5010–6PubMedCrossRef
231.
Sohail M, Hochegger H, Klotzbucher A, et al. Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo. Nucleic Acids Res 2001; 29(10): 2041–51PubMedCrossRef
232.
Ramezani A, Joshi S. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozymemediated cleavage in vitro and in vivo. Antisense Nucleic Acid Drug Dev 1996; 6(3): 229–35PubMedCrossRef
233.
Matveeva O, Felden B, Tsodikov A, et al. Prediction of antisense oligonucleotide efficacy by in vitro methods. Nat Biotechnol 1998; 16(13): 1374–5PubMedCrossRef
234.
Grassi G, Grassi M, Platz J, et al. Selection and characterization of active hammerhead ribozymes targeted against cyclin E and E2F1 full-length mRNA. Antisense Nucleic Acid Drug Dev 2001; 11(5): 271–87PubMedCrossRef
235.
Mir AA, Lockett TJ, Hendry P. Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers. Nucleic Acids Res 2001; 29(9): 1906–14PubMedCrossRef
236.
Sorg RV, Enczmann J, Sorg UR, et al. Identification of an alternatively spliced transcript of human interleukin-4 lacking the sequence encoded by exon 2. Exp Hematol 1993; 21(4): 560–3PubMed
237.
Altschuler M, Tritz R,Hampel A. A method for generating transcripts with defined 5′and 3′termini by autolytic processing. Gene 1992; 122(1): 85–90PubMedCrossRef
238.
Chowrira BM, Pavco PA, McSwiggen JA. In vitro and in vivo comparison of hammerhead, hairpin, and hepatitis delta virus self-processing ribozyme cassettes. J Biol Chem 1994; 269(41): 25856–64PubMed
Metadaten
Titel
A Multi-Model Approach to Nucleic Acid-Based Drug Development
verfasst von
Dr Isabelle Gautherot
Regís Sodoyer
Publikationsdatum
01.01.2004
Verlag
Springer International Publishing
Erschienen in
BioDrugs / Ausgabe 1/2004
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI
https://doi.org/10.2165/00063030-200418010-00004

Weitere Artikel der Ausgabe 1/2004

BioDrugs 1/2004 Zur Ausgabe

Novel Therapeutic Strategies

Novel Strategies for the Prevention of Bypass Graft Failure

Novel Therapeutic Strategies

Proinflammatory Cytokines in the Treatment of Bacterial and Fungal Infections

Technology Review

Expression Systems for the Production of Recombinant Pharmaceuticals

Short Communication

Intravenous Immunoglobulin Plus Interferon-α in Autoimmune Hepatitis C

Novel Therapeutic Strategies

Cytokines as Therapeutic Targets for Osteoarthritis